Related Experiment Video
Updated: May 20, 2025

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog
Published on: November 5, 2014
PARP7 as a new target for activating anti-tumor immunity in cancer
Katerina Popova1,2,3, Johannes Benedum1,2,4,5,6, Magdalena Engl1,2,4,5,6
1Department of Radiation Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Abstract:
ADP-ribosyl transferases (ARTs) are a family of enzymes which catalyze the addition of a chain (PARylation) or a single moiety (MARylation) of ADP-ribose to their substrates. PARP7 is a mono-ADP-ribosyl transferase (mono-ART) which has recently gained attention due to its emerging role as a negative regulator of the type I interferon (IFN-I) and nuclear receptor signaling, and due to its aberrant expression in cancer, contributing to disease progression and immune evasion. PARP7-mediated ADP-ribosylation can differentially affect protein stability. On the one hand, PARP7-mediated ADP-ribosylation of the transcription factor FRA1 protects it from proteosomal degradation and thereby supports its function in negatively regulating IRF1 and the expression of apoptosis and immune signaling genes. On the other hand, PARP7-mediated ADP-ribosylation of aryl hydrocarbon receptor (AHR) and estrogen receptor (ER) marks them for proteosomal degradation. PARP7 also ADP-ribosylates the ligand-bound androgen receptor (AR), which is recognized by DTX3L-PARP9 that modulate the AR transcriptional activity. In this review, we discuss PARP7 enzymatic properties, biological functions and known substrates, its role in various cancers, and its targeting by specific inhibitors.
Related Concept Videos
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
PI3K/mTOR/AKT Signaling Pathway
Tumor Immunotherapy
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

